Primary immune thrombocytopenia (ITP) is a rare autoimmune disease characterized by a decreased platelet count, leading to an increased risk of bleeding. For refractory ITP, a more complex and expensive approach is required. In recent years, thrombopoietic receptor agonists (TPORAs) have become a commonly used option, but in many cases, patients still require extras**.
This study aims to assess the need and burden of refractory primary ITP, as well as the efficacy of TPORAS in the real world. We analysed sales data for two commonly used TPORAS (romiplostim and eltrombopag) on the French market, combined with relevant study data, to assess the prevalence and patient burden of refractory primary ITP.
The results of the study show that the prevalence of refractory primary ITP is high and places a heavy burden on patients and society. Although TPORAS has a certain effect in **, there are still some patients who cannot obtain satisfactory results with such drugs**. Of these, 6 13 patients received rituximab after two sessions of TPORAS**, 37Nine percent of refractory patients require a combination of TPORA and immunosuppressants**.
In the face of the needs and challenges of patients with refractory ITP, we need to continuously explore new strategies and methods. Future research should focus on improving outcomes and reducing healthcare costs to better meet the needs of patients and reduce the burden on society. At the same time, we also need to strengthen international cooperation and multidisciplinary research and application to provide more comprehensive and personalized solutions.